{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-004451","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.291520+00:00","generated_at":"2026-05-16T05:35:16.706594+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Skye Bioscience reports 52-week weight loss of 22.3% for nimacimab+semaglutide combo; no plateau observed","bullets":["Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.","Weight regain at 13-week off-therapy follow-up was 17.8% for combo vs 37.3% for semaglutide alone, a >50% reduction in rebound.","No serious adverse events or AESIs reported during 52-week extension; safety profile maintained.","Full topline Phase 2a extension data expected in Q3 2026; cash runway into Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-004451","json":"https://secwatch.observer/filing/0001628280-26-004451.json","markdown":"https://secwatch.observer/filing/0001628280-26-004451.md","text":"https://secwatch.observer/filing/0001628280-26-004451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/0001628280-26-004451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:35:16.706594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}